2020
Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts
Lapidot R, Shea KM, Yildirim I, Cabral HJ, Pelton SI, Health T. Characteristics of Serotype 3 Invasive Pneumococcal Disease before and after Universal Childhood Immunization with PCV13 in Massachusetts. Pathogens 2020, 9: 396. PMID: 32455770, PMCID: PMC7281000, DOI: 10.3390/pathogens9050396.Peer-Reviewed Original ResearchPneumococcal conjugate vaccineIPD casesIncidence rate ratiosIPD incidencePCV-13Disease characteristicsSerotype 3 invasive pneumococcal diseaseInvasive pneumococcal disease incidenceImpact of PCV13Presence of comorbiditiesInvasive pneumococcal diseasePneumococcal disease incidenceUniversal childhood immunizationWaning of immunityPassive surveillance systemPCV13 dosePCV13 introductionVaccine effectivenessConjugate vaccineMassachusetts childrenPneumococcal diseaseClinical syndromeChildhood immunizationIncidence ratePCV13
2018
1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease
Yildirim I, Little B, Shea K, Pelton S, Massachusetts M. 1430. Evolving Impact of 13-Valent Pneumococcal Conjugate Vaccine on Invasive Pneumococcal Disease. Open Forum Infectious Diseases 2018, 5: s441-s442. PMCID: PMC6253418, DOI: 10.1093/ofid/ofy210.1261.Peer-Reviewed Original ResearchInvasive pneumococcal diseaseStreptococcus pneumoniaeIPD casesPneumococcal diseaseVaccine serotypesIncidence of IPDCommon clinical presentationIntroduction of PCV13Pneumococcal conjugate vaccineOverall mortality rateChildhood immunization scheduleSickle cell diseaseYears of ageEnhanced surveillance systemIPD incidenceCommon comorbiditiesConjugate vaccineMassachusetts childrenClinical presentationImmunization scheduleCurrent epidemiologyCNS diseaseHematologic malignanciesCell diseaseClinical data
2015
Vaccination, Underlying Comorbidities, and Risk of Invasive Pneumococcal Disease
Yildirim I, Shea KM, Little BA, Silverio AL, Pelton SI. Vaccination, Underlying Comorbidities, and Risk of Invasive Pneumococcal Disease. Pediatrics 2015, 135: 495-503. PMID: 25647674, DOI: 10.1542/peds.2014-2426.Peer-Reviewed Original ResearchMeSH KeywordsBacterial CapsulesChildChild, PreschoolComorbidityFemaleFollow-Up StudiesHumansIncidenceInfantMaleMassachusettsPneumococcal InfectionsPneumococcal VaccinesPopulation SurveillancePrognosisRetrospective StudiesRisk AssessmentRisk FactorsStreptococcus pneumoniaeVaccinationVaccines, ConjugateConceptsInvasive pneumococcal diseasePneumococcal diseaseUnderlying conditionOutcomes of IPDPrevention of IPDChildhood invasive pneumococcal diseasePneumococcal vaccination statusPolysaccharide pneumococcal vaccineYear of diagnosisPrimary care providersCase fatality rateChronic respiratory diseasesImmunocompromising conditionsIPD diagnosisUnderlying comorbiditiesImmunization PracticesIPD casesPneumococcal vaccineVaccination statusConjugate vaccineMassachusetts childrenClinical presentationSerotype distributionHigher hospitalizationClinical data
2012
Evolving Picture of Invasive Pneumococcal Disease in Massachusetts Children
Yildirim I, Stevenson A, Hsu KK, Pelton SI. Evolving Picture of Invasive Pneumococcal Disease in Massachusetts Children. The Pediatric Infectious Disease Journal 2012, 31: 1016-1021. PMID: 22673142, DOI: 10.1097/inf.0b013e3182615615.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnti-Bacterial AgentsChildChild, PreschoolCluster AnalysisFemaleHeptavalent Pneumococcal Conjugate VaccineHumansIncidenceInfantMaleMassachusettsMeningitis, PneumococcalMicrobial Sensitivity TestsMultilocus Sequence TypingPneumococcal VaccinesProspective StudiesSepsisSerotypingStreptococcus pneumoniaeConceptsInvasive pneumococcal diseasePneumococcal conjugate vaccine serotypesPneumococcal conjugate vaccineIPD incidence ratesMassachusetts childrenPCV7 eraIPD casesPneumococcal diseaseConjugate vaccineVaccine serotypesSerotype 19AIncidence rateCases of IPDChildhood invasive pneumococcal diseaseHeptavalent pneumococcal conjugate vaccinePopulation-based surveillanceOverall IPD incidence ratesCeftriaxone-resistant isolatesYears of ageAntimicrobial susceptibility testingBacteremic pneumoniaPCV7 serotypesMultilocus sequence typingNonvaccine serotypesClinical presentation
2010
Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease
Yildirim I, Hanage WP, Lipsitch M, Shea KM, Stevenson A, Finkelstein J, Huang SS, Lee GM, Kleinman K, Pelton SI. Serotype specific invasive capacity and persistent reduction in invasive pneumococcal disease. Vaccine 2010, 29: 283-288. PMID: 21029807, PMCID: PMC3139683, DOI: 10.1016/j.vaccine.2010.10.032.Peer-Reviewed Original ResearchConceptsInvasive pneumococcal diseaseInvasive capacityPneumococcal diseaseIncidence of IPDNew pneumococcal conjugate vaccinesPneumococcal conjugate vaccineSterile body sitesStreptococcus pneumoniae serotypesCarriage serotypesNasopharyngeal acquisitionNP carriagePCV eraReplacement serotypesIPD incidenceRespiratory seasonsConjugate vaccineMassachusetts childrenCarriage prevalenceCommon serotypesPneumoniae serotypesOngoing surveillanceEnhanced surveillanceBody sitesPersistent reductionSerotype X